PBMs are hogging drug discounts
By Peter J. Pitts
The Trump administration has aimed a dagger at the heart of high pharmacy bills — the go-betweens in the supply chain that have been gouging insurers, drugmakers, and consumers.
Through its blueprint to reduce drug spending — called American Patients First — the administration invited public comment on the role of pharmacy benefit managers, or PBMs. These are the mega-corporations that health insurers hire to administer their drug benefits.
Officials surely got an earful. In their role as go-betweens, PBMs negotiate big discounts from drugmakers. But rather than passing those savings on to insurers and consumers, they have found ways to pocket much of the proceeds for themselves.
The sums involved are huge. If just one-third of the total discounts PBMs negotiate for Medicare’s drug benefit were passed on to patients at the pharmacy counter, seniors would have nearly $20 billion more in their pockets over the next decade. The top three PBMs — Express Scripts, CVS Caremark, and OptumRx, who together control 75 percent of the market — collected more than $10 billion in profits in 2015.
A recently leaked contract reveals the tactics PBMs use to secure savings for themselves.
First, PBMs tend to hog rebates. Drug manufacturers offer PBMs a percentage discount or negotiated “rebate” off a drug’s list price. In exchange, the PBM agrees to cover the drug under its affiliated insurance plans, thus making it available to more consumers.
The majority of rebate dollars should, in theory, flow back to health plans. Then the plans can pass those savings to patients in the form of lower premiums or out-of-pocket expenses.
But the leaked contract with Express Scripts, the nation’s largest PBM, gets crafty with its definition of “rebate.” The contract carves out so many exceptions to the “rebate” that the PBM itself ends up retaining most of the negotiated discounts for itself.
For instance, PBMs receive extra “inflation payments” from drug manufacturers to cover annual increases in a drug’s list price. But these payments are not classified as rebates. Similarly, PBMs charge drug companies “administrative fees,” “service fees,” and more for their services. But these fees also aren’t considered rebates. So PBMs don’t pass them along to health plans.
Second, the document reveals that Express Scripts uses cryptic algorithms to reclassify generic drugs as brand-name drugs. Drugmakers usually offer higher discounts for generics than they do for brand drugs. If a PBM gets a big discount on a generic drug and then reclassifies it as a brand drug, it avoids passing along the full discount to the health plan it’s representing. The PBM essentially buys the drug low, sells it high, and pockets the excess.
PBMs are knowingly profiting off the backs of American patients, pharmacists, and innovators. It’s time for them to change their shady practices — and pass on discounts to patients. The sunlight the Trump administration is calling for will be a great disinfectant.
Peter J. Pitts, a former Food and Drug Administration associate commissioner, is president of the Center for Medicine in the Public Interest.
The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.
How to submit an article, guest opinion piece, or letter to the editor to The Independent
Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:
—Submissions should be between 300 and 1,500 words.
—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.
—The subject line of the email containing your submission should read “Letter to the editor.”
—Attach your name to both the email and the document file (we don’t run anonymous letters).
—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.
—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.
Articles related to “PBMs are hogging drug discounts”
Canada Drugs scandal reveals the dangers of drug importation
